ArticleJournal of inflammation research2026
Vagus Nerve Stimulation Mitigates Sepsis-Induced Lung Injury via Pulmonary proBDNF Suppression.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated acute respiratory distress syndrome (ARDS) remains a major contributor to mortality among critically ill patients. Vagus nerve stimulation (VNS) may attenuate inflammatory injury, but the downstream molecular mechanisms underlying its protective effects in septic lung injury remain incompletely understood. The role of proBDNF in VNS-mediated immunoregulation remains unclear. This study aimed to explore whether pulmonary proBDNF contributes to VNS-induced protection against sepsis-associated lung injury. Methods: Sepsis-associated lung injury was induced by cecal ligation and puncture (CLP) in rats. The effects of VNS on lung injury, inflammation, and pulmonary proBDNF expression were evaluated. Vagotomy was conducted to assess the dependence of VNS effects on intact vagal signaling. Peripheral cholinergic signaling was probed using methyllycaconitine, an α7 nicotinic acetylcholine receptor (α7nAChR) antagonist. Pulmonary overexpression of proBDNF was achieved via adeno-associated virus (AAV) delivery to determine its functional significance. Histological, molecular, and functional analyses assessed lung injury, inflammation, pulmonary proBDNF, pulmonary edema, and BALF total protein levels. Results: VNS significantly alleviated CLP-induced lung injury, reduced pulmonary inflammatory cytokine expression, decreased pulmonary edema and BALF total protein levels, and partially restored barrier-associated gene expression. Pulmonary proBDNF levels were markedly increased after CLP but suppressed by VNS, whereas vagotomy further elevated proBDNF. Brain proBDNF levels remained largely unchanged across groups. α7nAChR blockade attenuated the inhibitory effect of VNS on pulmonary proBDNF. Immunofluorescence identified macrophages as a major source of proBDNF in injured lungs. Notably, AAV-mediated pulmonary overexpression of proBDNF weakened the beneficial effects of VNS on inflammation, pulmonary edema, alveolar-capillary barrier leakage, and lung damage. Conclusion: VNS protects against sepsis-associated lung injury through suppression of elevated pulmonary proBDNF, a process dependent on intact vagal signaling and, at least in part, mediated by α7nAChR-dependent peripheral cholinergic pathways. These findings identify proBDNF as a possible downstream effector of VNS-mediated lung protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.